Lavipharm S.A.

ATSE:LAVI Stock Report

Market Cap: €265.7m

Lavipharm Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Telemaque Lavidas

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.4yrs
CEO ownershipn/a
Management average tenure2.4yrs
Board average tenure5yrs

Recent management updates

Recent updates

Analysis Article • May 01

Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) Shareholders

Lavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...
Analysis Article • Jan 28

Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance Completely

Despite an already strong run, Lavipharm S.A. ( ATH:LAVI ) shares have been powering on, with a gain of 27% in the last...
Analysis Article • Dec 18

Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Apr 10

We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) Profit

The latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...
Analysis Article • Sep 26

Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They Appear

Despite posting strong earnings, Lavipharm S.A.'s ( ATH:LAVI ) stock didn't move much over the last week. We looked...
Analysis Article • Aug 06

Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E Ratio

With a price-to-earnings (or "P/E") ratio of 61.9x Lavipharm S.A. ( ATH:LAVI ) may be sending very bearish signals at...
Analysis Article • Nov 01

Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt Burden

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Feb 11

We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory Profitability

Broadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...

CEO

Telemaque Lavidas

2.4yrs
Tenure

Mr. Telemaque Jean Lavidas is Director of Center For Community Alternatives, Inc. Telemaque Lavidas serves as the President of Lavipharm Group International, a diversified healthcare group of companies act...

Leadership Team

NamePositionTenureCompensationOwnership
Telemaque Lavidas
CEO & Executive Board Member2.4yrsno datano data
Vassilis Baloumis
Group CFO & Investor Relations Officer4.5yrsno datano data
Panagiotis Kousoulis
Chief Manufacturing & Operations Officerno datano datano data
Evangelos Paterakis
Chief Accountantno datano datano data
Mariza Antonaki
Chief People & Technology Officer2.4yrsno datano data
Nikos Ladas
Chief Scientific Officer2.4yrsno datano data
Eleana Nikolopoulou
Director of Legal & Compliance and Corporate Secretary4.3yrsno datano data
Ilias Konstantopoulos
Director of Marketing & Sales CHCno datano datano data
Katerina Tsardaka
Director of Business Development & Acquisitions2.4yrsno datano data
Panagiotis Giannouleas
Deputy CEO & Director2.4yrsno datano data
Emmanouil Petrou
Head of Medical Affairs of Lavipharm Hellasno datano datano data
Ioannis Sarigiannidis
Chief Commercial Officer International2.4yrsno datano data
2.4yrs
Average Tenure

Experienced Management: LAVI's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Telemaque Lavidas
CEO & Executive Board Member7yrsno datano data
Panagiotis Giannouleas
Deputy CEO & Director2.4yrsno datano data
Venetsiana-Loukia Lavida
Vice Chairman of the Boardno datano datano data
Christos Diamandopoulos
Non Executive Directorno datano datano data
James Christopoulos
Independent Non Executive Directorno datano datano data
Vicky Kefalas
Independent Non-Executive Board Member3.4yrsno datano data
Sophia Kounenaki-Efraimoglou
Independent Chairperson of the Board6.6yrsno datano data
5.0yrs
Average Tenure

Experienced Board: LAVI's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 21:51
End of Day Share Price 2026/06/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lavipharm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.